UHUzma Haque

Uzma Haque

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Uzma Haque has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characteristics associated with patient-reported treatment success in psoriatic arthritis

    by Christeen Samuel, Amanda Finney, Thomas Grader-Beck, Uzma Haque, John Miller, Suzanne M Grieb, Laura Prichett, Ana-Maria Orbai

    To determine characteristics associated with patient-reported treatment success in psoriatic arthritis (PsA). Rheumatologist-diagnosed PsA patients fulfilling the CASPAR classification were recruited from a single center. PsA outcome measures included: 66/68 swollen/tender joint counts, Leeds/SPARCC dactylitis/enthesitis indices, psoriasis body surface area (BSA), and patient-reported outcomes (PROs) including PROMIS. The primary outcome was a patient-reported item: “Today, considering the level of control of your psoriatic arthritis and psoriasis, do you consider your treatment has been successful?” Descriptive and multivariate logistic regression analyses identified clinical predictors of patient-reported treatment success. Patient-reported reasons for lack of treatment success were explored. A total of 178 participants had a baseline visit. Mean (SD) CASPAR score was 3.7 (0.9), age 51.7 (13.5) years, and BMI 31.3 (7.2) kg/m2. Fifty-two percent were women, and 86.0% white. Treatment success was reported by 116/178(65%) patients in the analytic cohort. Among 76 patients who reported treatment failure, the most frequently selected reasons for lack of success were pain (n = 55, 72.4%), fatigue (n = 46, 60.5%), inflamed joints (n = 40, 52.6%), and stiffness (n = 40, 52.6%). Overall, 105 participants had complete data across variables in the logistic regression models. Patient-reported treatment success was independently associated with the 66-swollen/68-tender joint counts, psoriasis BSA, PROs (pain interference, physical function, fatigue), and TNF-inhibitor therapy, after controlling for BMI and demographics. Patient-reported treatment success in PsA may be achieved through improvement of inflammatory arthritis, psoriasis, pain, physical function, fatigue, and the use ofTNF-inhibitors. Patients reported treatment failure was most commonly due to symptoms of pain, fatigue and stiffness.


  • Open Access

    Clinical Images: Frosted branch angiitis in systemic lupus erythematosus

    by Brittany C. Tsou, Loka Thangamathesvaran, Ravi Pandit, Maximilian F. Konig, Uzma Jalal Haque

  • Cannabis arteritis revisited: a case report with distinct pathologic features and review of the literature

    by Timothy Kaniecki, Tait H Huso, Uzma J Haque

    Timothy Kaniecki, Tait H Huso, Uzma J Haque; Cannabis arteritis revisited: a case report with distinct pathologic features and review of the literature, Rheumat


  • Amassing the Evidence

    by Eric J. Dein, Zsuzsanna H. McMahan, Allan C. Gelber, Uzma J. Haque

  • Open Access

    Anti-Smith Antibody Positivity Without Lupus in the Setting of Lung Cancer

    by Homa Timlin, Kirthi Machireddy, Jennifer Shiroky, Srekar Ravi, Uzma Haque

    The interpretation of positive serologic findings in cancer sera remains controversial. Selected antinuclear antibodies (ANAs), such as anti-double-stranded deoxyribonucleic acid (dsDNA) and anti-Smith, are highly specific for the diagnosis of systemic lupus erythematosus (SLE). On the other hand, the ANA titer is sensitive but not specific for SLE and has been reported in healthy individuals, various infections, other autoimmune diseases and cancer. We report for the first time positive anti-Smith antibody in two patients without lupus in the setting of lung cancer.


  • Open Access

    Clinical Characteristics of Hydralazine-induced Lupus

    by Homa Timlin, Michael Wu, Monica Crespo-Bosque, Duvuru Geetha, Ashley Ingolia, Uzma Haque, Marilyn C. Towns, Thomas Grader-Beck

    The use of hydralazine has been associated with the development of lupus erythematosus and lupus-like syndromes. We performed this retrospective study to identify clinical characteristics of individuals who developed hydralazine-induced lupus. We performed a single-center retrospective review of seven individuals who had a diagnosis of hydralazine-induced lupus by International Classification of Diseases, Ninth Revision (ICD9) code and were on hydralazine prior to their diagnosis. Clinical and laboratory data were obtained from a review of the medical record up to 12-month follow-up. Of the seven individuals with hydralazine-induced lupus, five were Caucasian (71%) and two were African-American. The mean age at the time of diagnosis was 62 years. Four (57%) were male. The majority of individuals were exposed to hydralazine for more than 12 months (83%). Four individuals had biopsy-proven lupus nephritis and four individuals had cardiopulmonary and skin involvement. Six patients were positive for antinuclear antibody (ANA) with a homogenous pattern, and five of those were positive for anti-histone antibody. Additionally, positive anti-double-stranded DNA (anti-dsDNA) antibody, anti-cardiolipin antibodies, low complements, positive lupus anticoagulant, and leukopenia were seen in 42% of our cohort. Of the five individuals in whom anti-myeloperoxidase (MPO) antibody was strongly positive, all had renal involvement defined by an elevated creatinine with three having biopsy-proven lupus nephritis. Three other individuals with MPO positivity had concurrent cardiopulmonary and skin involvement. Four individuals were positive for anti-proteinase 3 (PR3) antibody, three of whom were strongly positive with renal involvement defined by an elevated creatinine with two having biopsy-proven lupus nephritis. The level of anti-dsDNA antibody and anti-PR3 antibody normalized at three months while anti-MPO antibody took 12 months to normalize following cessation of hydralazine. When checked, low complement component 3 (C3) and anti-histone antibody persisted past 12 months. In addition to the withdrawal of hydralazine, six individuals were treated with hydroxychloroquine and five with mycophenolate mofetil. Three of four individuals with renal involvement received plasmapheresis and two received cyclophosphamide and hemodialysis. Hydralazine can aggravate and unmask incipient lupus. Since the presentation can be varied, early recognition of symptoms is critical. Precautions should be taken before initiating this medication in individuals with certain risk factors. Once diagnosed, potential serological findings such as a positive anti-MPO/anti-PR3 antibody could predict more severe manifestations such as pulmonary-renal complications.


  • Open Access

    Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE)

    by Jason Liebowitz, Derek Fine, Philip Seo, Michelle Petri, Kirthi Machireddy, Uzma Haque, Rebecca Manno, Homa Timlin

    Glomerulonephritis (GN) in lupus is generally an immune complex glomerulonephritis from the deposition of immunoglobulin and complements. Pauci-immune GN is the most common cause of rapidly progressive GN and is frequently associated with an anti-nuclear cytoplasmic antibody (ANCA). We report a patient with a history of systemic lupus erythematosus who presented with worsening proteinuria and was subsequently diagnosed with pauci-immune GN on renal biopsy, in the absence of ANCA.


  • Open Access

    Fevers in Adult Lupus Patients (vol 10, e2098, 2018)

    by Homa Timlin, Abrahim Syed, Uzma Haque, Brittany Adler, Genevieve Law, Kirthi Machireddy, Rebecca Manno

    The following funding acknowledgement was erroneously omitted from the original published article: BA was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institute of Health under Award Number T32AR048522.

  • Open Access

    Mycophenolate Mofetil in a Lupus Patient with Pulmonary Hypertension

    by Kirthi Machireddy, Zin Myint, Eric Dein, Stephen C. Mathai, Philip Seo, Uzma Haque, Rebecca Manno, Homa Timlin

    Pulmonary hypertension (PH) is a life-threatening complication of several, different connective tissue diseases, including systemic lupus erythematous (SLE), systemic sclerosis, and rheumatoid arthritis. PH can present early in SLE. The severity does not correlate with other organ disease activity or with disease duration. It is still debatable whether immunosuppressive therapy is useful for PH related to SLE or autoimmune connective tissue disease, as there are no large clinical trials. However, several case reports have shown improvement with cyclophosphamide and prednisone with or without vasodilator therapy. We present a case of SLE-related PH in which a dramatic improvement in mean pulmonary artery pressure and exercise capacity was noted after the institution of treatment with mycophenolate mofetil, resulting in a decrease in corticosteroid dose. Our observations support the potential value of mycophenolate mofetil therapy for PH in SLE.


  • Vitamin D and arthritis

    by U.J. Haque

    Vitamin D is a pleiotropic steroid molecule that exerts its physiological effects through the ubiquitous vitamin D receptor. Vitamin D is formed from its precursor in the skin upon exposure to the sunlight. Its importance in calcium homeostasis has been well known for a century, but recently several non-calcemic effects have been recognized. Vitamin D regulates several genes involved in cellular differentiation, apoptosis and has immunomodulatory effects. Epidemiologic data suggest that vitamin D deficiency may increase the risk of common cancers and autoimmune diseases. In experimental animal models, autoimmune diseases can be ameliorated by treatment with active vitamin D metabolites. Potential use of vitamin D supplementation to modify these diseases would certainly be a novel approach. Preliminary data from cross-sectional studies show that low vitamin D levels may be associated with increased disease activity in rheumatoid arthritis. Other studies show a possible increased risk of osteoarthritis with low vitamin D levels. These findings, while interesting, are not confirmed by all studies. Moreover, the cross-sectional design of these studies does not establish causality. Currently, the optimal and minimal level of vitamin D required for its physiological functions in humans is unknown. We, thus, await more research and randomized controlled interventional trials to answer these critical questions.